Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to improve treatment of Moderate Aplastic Anemia (MAA) by evaluating
the safety and efficiency of Eltrombopag as a new treatment option in patients with therapy
requiring MAA.